

are paying now, although mostly for care of end-stage complications. In addition, a recent study⁷ has shown that increases in worker productivity may offset the increase in the cost of providing intensive glycemic control.

REFERENCES

- 1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
- 2. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996; 276:1409-1415.
- 3. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18:258-268.
- 4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1996; 28:103-117.
- 5. Eastman, RC, Javitt JC, Herman, WH, et al. Model of complications of NIDDM: I. Model construction and assumptions. Diabetes Care 1997; 20:725-734.
- 6. Eastman, RC, Javitt JC, Herman, WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectivenss of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20:735-744.
- 7. Testa M, Simonson D. Health economic benefits of improved glycemic control in NIDDM. Diabetes 1997; 46(Suppl 1):36A.


ADDRESS: Richard C. Eastman, MD, National Institute of Diabetes and Digestive and Kidney Diseases, Bldg 31 Rm 9A16, 31 Center Dr MSC 2560, National Institutes of Health, Bethesda, MD 20892-2560.

CORRECTION

The special supplement "Clinical practice guidelines: renal cell carcinoma"1 contained an error. On page SI-29, a dosage of rHuIFN-α cited from preliminary results of a study by S. Negrier et al² was reported as 6×10^6 IU SC three times each week for both monotherapy and combination therapy. While this was the correct dosage for rHuIFN-α in combination with rHuIL-2, the correct dosage of rHuIFN- α as monotherapy should read 18 × 106 IU SC three times each week.

REFERENCES

- 1. Bukowski RM, Novick RM. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med 1997; 64(Suppl
- Negrier S, Escudier B, Lasset C, et al. The FNCLCC Crecy trial: interleukin 2 (IL2) + interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC) [abstract]. Proc Am Soc Clin Oncol 1996; 15:248.



Dear Doctor:

As editors, we'd like you to look into every issue, every page of the Cleveland Clinic Journal of Medicine. We'd like to know...

1. How many ISSUES do you look into per YEAR?*

Here's our goal:

☐ 34–66% **ऑ** 67–100% ☐ None ☐ 1–33%

2. How many PAGES do you look into per ISSUE?

Here's our goal:

□ None □ 1–33% □ 34–66% **1** 67–100%

We put it in writing... please put it in writing for us.

We want to hear from you.

E-mail: ccim@cesmtp.ccf.org

WWW: http://www.ccf.org/ed/ccjhome.htm

Cleveland Clinic Journal of Medicine The Cleveland Clinic Foundation, EE37

9500 Euclid Avenue Cleveland, Ohio 44195

Phone: 216.444.2661 Fax: 216.444.9385

10 issues per

SEPTEMBER 1997